search
Back to results

Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG (MelanooMSOT)

Primary Purpose

Melanoma, Stage I, Melanoma, Stage II, Melanoma Stage III

Status
Not yet recruiting
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
MSOT
Sponsored by
University Medical Center Groningen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Melanoma, Stage I

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with grade Ib- III melanoma scheduled for SLNB and/or surgical excision.
  • Patients must be > 18 years old and be able to give informed consent.
  • Skintype I-IV following Fitzpatrick skin classification (MSOT less reliable in skin types >IV)

Exclusion Criteria:

  • Apparent hyperthyroidism or autonomous thyroid adenoma of the thyroid gland
  • Prior surgery or radiotherapy on involved lymph nodes / area
  • Major surgery within 28 days before tracer administration
  • Pregnant or nursing women, fertile women will need a negative pregnancy test prior to inclusion
  • History of iodine allergy or anaphylactic reactions to insect bites
  • Hypersensitivity to ICG or poorly tolerated ICG in the past
  • Unexplained allergic reaction in the past
  • Skin type >IV following Fitzpatrick skin classification (MSOT less reliable)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Standard of care + MSOT

    Arm Description

    Standard of care + MSOT

    Outcomes

    Primary Outcome Measures

    Concordance rate of SLNs identified by MSOT imaging and ICG versus the standard of care with 99mTc-nanocolloid Tc99m and lymphoscintigraphic imaging

    Secondary Outcome Measures

    Patient characteristics
    Age, sex, BMI, history and morbidity, localization and extent of primary tumor, baseline blood count/liver and kidney function

    Full Information

    First Posted
    July 1, 2022
    Last Updated
    July 15, 2022
    Sponsor
    University Medical Center Groningen
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05467137
    Brief Title
    Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG
    Acronym
    MelanooMSOT
    Official Title
    Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MultiSpectral Optoacoustic Tomography (MSOT) and IndoCyanine Green (ICG)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 2022 (Anticipated)
    Primary Completion Date
    November 2022 (Anticipated)
    Study Completion Date
    March 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University Medical Center Groningen

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    In this study the investigators try to identify the sentinel lymph node in patients with stage Ib-III melanoma in a non-invasive manner without the use of a radioactive tracer by using the new MSOT technology.
    Detailed Description
    Over the past few decades, melanoma has been one of the fastest-growing cancers and the incidence rate of melanoma is still increasing. Standard treatment for melanoma is wide (re)excision. Sentinel lymph node (SLN) biopsy (SLNB) is recommended for patients with melanoma of AJCC stage pT1b or higher according to Dutch guidelines. SLNB provides essential staging information that impacts on the clinical management of patients with melanoma, and the presence of SLN metastasis indicates a significantly worse prognosis. However, the overall complication rate of SLNB is high. Currently, lymphoscintigraphy using 99mTc-nanocolloid Technetium-99m-nanocolloïd (Tc99m) is the gold standard to identify the sentinel lymph node. However, there are various disadvantages of using 99mTc-nanocolloidTc99m: the involvement of radioisotopes represents a radioactive burden for patients and caregivers, the lymphoscintigraphic imaging has poor spatial resolution, and the involvement of radioisotopes is expensive and creates logistic challenges. Therefore, in this study the goal is to identify the sentinel lymph node in a non-invasive manner without the use of a radioactive tracer. The investigators try to reach this goal by using the fluorophore dye IndoCyanine Green (ICG) and multispectral optoacoustic imaging (MSOT). MSOT is a new, but increasingly used, imaging modality that has emerged the field of optical imaging. MSOT is based on a highly powerful pulsed laser in different wavelengths. Photo absorbing molecules absorb laser light in a specific wavelength, undergo thermal expansion and create soundwaves which can be detected by special transducers. The MSOT combines conventional ultrasonography with optoacoustic imaging which gives both anatomical and biological information and is currently available in the University Medical Centre Groningen (UMCG).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Melanoma, Stage I, Melanoma, Stage II, Melanoma Stage III

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Phase 4
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    10 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Standard of care + MSOT
    Arm Type
    Experimental
    Arm Description
    Standard of care + MSOT
    Intervention Type
    Device
    Intervention Name(s)
    MSOT
    Intervention Description
    MSOT imaging (after ICG injection)
    Primary Outcome Measure Information:
    Title
    Concordance rate of SLNs identified by MSOT imaging and ICG versus the standard of care with 99mTc-nanocolloid Tc99m and lymphoscintigraphic imaging
    Time Frame
    Through study completion (an average of 1 year)
    Secondary Outcome Measure Information:
    Title
    Patient characteristics
    Description
    Age, sex, BMI, history and morbidity, localization and extent of primary tumor, baseline blood count/liver and kidney function
    Time Frame
    Through study completion (an average of 1 year)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients with grade Ib- III melanoma scheduled for SLNB and/or surgical excision. Patients must be > 18 years old and be able to give informed consent. Skintype I-IV following Fitzpatrick skin classification (MSOT less reliable in skin types >IV) Exclusion Criteria: Apparent hyperthyroidism or autonomous thyroid adenoma of the thyroid gland Prior surgery or radiotherapy on involved lymph nodes / area Major surgery within 28 days before tracer administration Pregnant or nursing women, fertile women will need a negative pregnancy test prior to inclusion History of iodine allergy or anaphylactic reactions to insect bites Hypersensitivity to ICG or poorly tolerated ICG in the past Unexplained allergic reaction in the past Skin type >IV following Fitzpatrick skin classification (MSOT less reliable)
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jutten
    Phone
    0031 50 361 6161
    Email
    e.jutten@umcg.nl
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    van Leeuwen
    Organizational Affiliation
    University Medical Center Groningen
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG

    We'll reach out to this number within 24 hrs